Avidity

RNA

ATLANTA, GA – – (Newsfile Corp. – September 29, 2022) – – Holzer & Holzer, LLC is investigating whether Avidity Biosciences, Inc.  (“Avidity” or the “Company”) (NASDAQ: RNA) complied with federal securities laws.  On September 27, 2022, Avidity announced that the U.S. Food and Drug Administration has placed a partial clinical hold on new participant enrollment in its Phase 1/2 MARINA clinical trial following a serious adverse event. After this announcement, the Company’s stock price dropped.

If you purchased Avidity stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at  cholzer@holzerlaw.com  or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at https://holzerlaw.com/case/avidity/ to discuss your legal rights.

Registration Deadline

Lead Plaintiff Deadline Has Passed

Submit Your Information

Name(Required)
Address
MM slash DD slash YYYY
Shares Purchased(Required)
Number of Shares Acquired
Acquisition Price Per Share
 
MM slash DD slash YYYY
Shares Sold
Number of Shares Sold
Selling Price Per Share
 
By clicking on the button below, I am requesting Holzer & Holzer, LLC send me documents necessary to retain the firm.